BiotechTube
Home/Targinta/Peter Ekolind
PE

Peter Ekolind

Interim CEO

Targinta

Therapeutic Areas

Oncology

Targinta Pipeline

DrugIndicationPhase
TARG9Glioblastoma, Triple-Negative Breast CancerPre-clinical
TARG10Glioblastoma, Triple-Negative Breast CancerPre-clinical

Leadership Team at Targinta

EL
Evy Lundgren-Åkerlund
CSO (and CEO of parent company Xintela)
View full Targinta profile